SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) February 15, 1996
-----------------
Pharmos Corporation
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Nevada 0-11550 36-3207413
----------------- ---------------------- ----------------------
(State or other Commission File Number (I.R.S. Employer
jurisdiction of Identification Number)
incorporation or
organization
2 Innovation Drive, Alachua, FL 32615
---------------------------------------------------
(Address of principal executive offices) (zip code)
(904) 462-1210
---------------------------------------------------
(Registrant's telephone number including area code)
None
----------------------------------------------------
(Former name, former address and former fiscal year,
if changed since last report)
<PAGE>
Item 5 Other Events
Pharmos Corporation (the "Company") has received a favorable ruling from
the New York Supreme Court granting the Company's motion for a preliminary
injunction enjoining Dr. Nicholas Bodor from taking any steps to terminate or
interfere with the Company's rights under its License Agreement with Dr. Bodor
relating to its ophthalmic anti-inflammatory drug, Loteprednol Etabonate
("Lotemax TM"). In addition, the Court denied Dr. Bodor's motion to dismiss the
action for lack of personal jurisdiction. The Court's ruling was in an action
commenced by the Company in Supreme Court, New York County, on October 27, 1995.
In its Memorandum Decision, the Court found that "Pharmos has demonstrated
a likelihood of success on the merits," and held that Dr. Bodor "has not
demonstrated that the License Agreement prohibits the co-marketing of a product
that contains a licensed product, as opposed to the marketing of the licensed
product itself." The Court also instructed the parties to submit a proposed
order implementing the terms of the Court's Memorandum Decision and affidavits
regarding an appropriate undertaking (bond) by the Company pending a final
determination of the action.
<PAGE>
SIGNATURE PAGE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
PHARMOS CORPORATION
Date: February 15, 1996 /s/ S. Colin Neill
------------------ ------------------------------------
S. Colin Neill
Acting Chief Financial Officer
